Clinical significance of aberrant DEUP1 promoter methylation in hepatocellular carcinoma

QIWEN YU1,2*, SHENGLI CAO1,2*, HONGWEI TANG2, JIE LI1, WENZHI GUO1 and SHUIJUN ZHANG1,2

1Department of Hepatobiliary and Pancreatic Surgery; 2Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China

Received December 1, 2018; Accepted May 7, 2019

DOI: 10.3892/ol.2019.10421

Abstract. Accumulating studies have shown that methylation of tumor suppressor genes plays an important role in tumorigenesis. Deuterosome assembly protein 1 (DEUP1) has been implicated as a suppressor gene in some tumors and promoter methylation led to silencing of its expression. However, the roles of DEUP1 promoter methylation and expression in hepatocellular carcinoma (HCC) are not clear. In the present study, the expression and methylation of the DEUP1 promoter in HCC was investigated and the correlations with HCC occurrence and development were explored. A total of 60 HCC tumor and adjacent non-tumor tissues were included in this study. Reverse transcription-polymerase chain reaction, bisulfite PCR sequencing, immunohistochemistry and western blotting were applied to detect the methylation status of the DEUP1 promoter and its expression, and to analyze their associations with clinicopathological data. The results showed that the mRNA and protein expression of DEUP1 in adjacent non-tumor tissues was significantly increased compared with in the HCC tissues. DEUP1 promoter methylation was detected in 46/60 (76.7%) tumor tissues and there was a negative correlation between promoter methylation and DEUP1 protein expression (P<0.05). Analysis of the clinicopathological data revealed that the mRNA and protein expression of DEUP1, and its promoter methylation status, was associated with tumor node metastasis stage and tumor differentiation. Taken together, the results of the present study suggested that methylation of the DEUP1 promoter maybe an important mechanism for gene inactivation and has a critical role in the occurrence and development of liver cancer.

Introduction

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, its survival rate ranks only second to lung cancer and it is a severe threat to human health (1-4). However, the pathophysiological mechanisms involved remain unclear. The occurrence of HCC is a complicated process involving multiple genes and steps. Imbalances in cellular signal transduction pathways, deficiencies in DNA repair-regulating genes, activation of protooncogenes, inactivation of tumor suppressor genes and epigenetic modifications all promote the occurrence of liver cancer (1-4).

Epigenetics refers to the regulation of gene expression by affecting a gene's transcription and translation without changing DNA sequences, including DNA methylation, histone modification and abnormal miRNA expression (5,6). DNA methylation has been widely studied in a number of types of tumor (7). Methylation of DNA leads to the inactivation of tumor suppressor genes and promotes the occurrence and development of tumors (8). Reversion of DNA methylation events has been reported to inhibit the growth of tumor cells and promote tumor cell apoptosis (9).

Deuterosome assembly protein 1 (DEUP1) is a new candidate tumor suppressor gene and is associated with cellular signal transduction during tumor formation. Bioinformatics methods revealed that DEUP1expression was closely associated with the survival time of patients with HCC. Through database analysis, it was also demonstrated that the inactivation of DEUP1 was correlated with the methylation of its promoter. DEUP1 expression is absent or reduced in malignant tumors, such as gastric and thyroid cancer (10,11). However, its expression in HCC and the association with clinical information have not been reported on, to the best of our knowledge.

The present study was undertaken to explore the effects of DEUP1 in HCC, reverse transcription-polymerase chain reaction (RT-PCR), bisulfite PCR sequencing (BSP),
immunohistochemistry (IHC) and western blotting were conducted to detect methylation of the DEUP1 promoter and DEUP1 expression in 60 cases HCC and adjacent non-tumor tissues, and explore the correlations between DEUP1 and pathological features.

Materials and methods

Clinical information. HCC and adjacent non-tumor tissues (at least 3 cm from the surgical incision) were collected from 60 patients who underwent surgical resection between January 2016 and December 2016 at the First Affiliated Hospital of Zhengzhou University. All specimens were confirmed by pathological diagnosis. No patients underwent radiotherapy or chemotherapy prior to surgery. A total of 45 males and 15 females, aged 31-75 years old (median, 58 years), were recruited to the study. According to tumor node and metastasis (TNM) staging of the AJCC 2018 (12), 32 patients were stage I+II, and 28 were stage III+IV. Informed consent was obtained from each patient and the study protocol was approved by the Medical Ethics Committee of the First Affiliated Hospital of Zhengzhou University.

Relationship between DEUP1 mRNA expression and overall survival. Based on the KM Plotter Online Tool (http://kmplot.com/analysis/), 364 patients with HCC were divided into two groups according to the median expression of DEUP1 and Kaplan-Meier survival curve was then plotted. The best cutoff was auto-selected.

DEUP1 mRNA expression detected by RT-PCR. HCC and adjacent non-tumor tissues (100 mg each) were used. Total RNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol and the RNA concentration and A260/A280 ratio were measured using a Nanodrop 2000 (Thermo Fisher Scientific, Inc.). RNA (1 µg) was transcribed to cDNA using a reverse transcription kit (cat. no. RR047A; Takara Biotechnology Co., Ltd.) according to the manufacturer’s protocol. The primers were designed based on the gene coding sequence. DEUP1: 5’-CCT TCG ACA TTT CAA GCC AAA GA-3’ (forward primer) and 5’ -GAA ATG CTG TGC AGC CAA AGA-3’ (reverse primer). GAPDH: 5’ -CGC TGA GTA CGT CGT GGA GT-3’ (forward primer) and CAT CAC GCC ACA GTT TCC CG-3’ (reverse primer). TB Green Master Mix kit (Takara Biotechnology Co., Ltd.) was used with a total reaction volume of 20 µl containing 10 µl of 2X TB Green Master Mix, 2 µl of cDNA, 0.8 µl of upstream and downstream primers each, and 6.4 µl of ddH2O. Reaction conditions were as follows: Pre-denaturation at 95°C for 30 sec, denaturation at 95°C for 5 sec and annealing at 59.5°C for 30 sec, for a total of 40 cycles. Human GAPDH was used as an internal reference (5 µl) and loaded with PCR product (5 µl) and 6X DNA loading buffer (1 µl). After 2% agarose gel electrophoresis, the ratio of DEUP1 to GAPDH was compared using the average value of normal tissue as the standard. A ratio higher than the value of the standard or within the range was considered to indicate positive gene expression and no band present or a band lower than the normal range indicated no gene expression. Image J version 1.8.0 (National Institutes of Health) was used to semi-quantitatively analyze the gray scale ratio of target gene and GAPDH.
DEUP1 promoter methylation detected by BSP. DNA in the tissues was extracted using a TINamp Genomic DNA kit (Sangon Biotech, Co., Ltd.) and resolved via 1% agarose gel electrophoresis. The absorbance (260/280) was measured with a UV spectrophotometer to calculate DNA content. The DNA was modified with sulfite using an EZ DNA Methylation-Gold™ kit D5005 (Zymo Research Corp., Irvine, CA, USA). The primers were designed using Primer Premier 5 (Premier Biosoft International). BSP primers were as follows: Upstream: 5'-TTTAGAATAGGGGGTATTGGA-3'; downstream: 5'-AAACCTTACGGGTTCTCTC-3'. The BSP reaction volume was 20 µl. Cycle parameters were as follows: 95˚C pre-denaturation for 5 min, 95˚C denaturation for 30 sec, 61˚C annealing for 30 sec and 72˚C extension for 50 sec, for a total of 35 cycles, followed by extension at 72˚C for 8 min. The integrity of the PCR product (5 µl) was established by 1% agarose gel electrophoresis. The PCR product was ligated with a T-vector to generate 10 µl linking product that was transferred to 100 µl SK9307 competent cells using the Rapid Competent Cell Preps kit (cat. no. B529307; Sangon Biotech, Co., Ltd.). After screening using LB culture medium containing ampicillin (cat. no. A600894; Sangon Biotech, Co., Ltd.), five independent colonies were picked. The target fragment was identified by PCR and the products were sequenced.

DEUP1 protein changes detected by IHC. Paraffin sections of HCC and adjacent non-tumor tissues at 4 µm thickness were dewaxed and rehydrated with graded alcohol. Citric acid buffer was used for antigen retrieval under high temperature (heated to boiling and rested for 15 min at room temperature) Then, the sections were washed with PBS, blocked with normal goat serum (Beijing Solarbio Science & Technology Co., Ltd.) at 4˚C overnight. Afterwards, the sections were washed with PBS, incubated with a secondary antibody (1:100; cat. no. SP0021; Beijing Solarbio Science & Technology Co., Ltd.) labeled with biotin for 1 h at room temperature, washed again with PBS, incubated with horseradish peroxidase (HRP)-labeled streptavidin and then a DAB chromogenic reagent, washed with running water, re-stained with hematoxylin at room temperature until nuclei turned blue, dehydrated with gradient ethanol, sealed with gum, and then observed under a light microscope. The IHC results indicated faint yellow or even dark brown granules. Positive cell counting was scored as follows: <5%
was scored as 0, 5-25% as 1, 25-75% as 2, 50-75% as 3 and >75% as 4. Color intensity was scored as follows: No color was scored as 0, faint yellow as 1, pale brown as 2 and dark brown as 3. If the product of the two scores was ≥4, it was deemed positive.

**DEUP1 protein expression detected by western blotting.** A total of 100 mg of liver tissue, 1 ml RIPA (Beijing Solarbio Science & Technology Co., Ltd.) and 10 µl PMSF were placed into an EP tube and fully broken with a tissue breaker. The protein was extracted using RIPA buffer and the concentration was measured using a bicinchoninic acid Protein Assay kit (Beijing Solarbio Science & Technology Co., Ltd.). Then, 40 µg of total protein was resolved by SDS-PAGE (10%) and transferred onto 0.45 µm nitrocellulose membranes. The membranes were blocked with 5% non-fat milk at room temperature for 1 h, following which primary antibodies against DEUP1 (1:1,000; cat. no. ab102688; Abcam) and GAPDH (1:1,000; Cell Signaling Technology, Inc.; cat. no. 5174) were added and incubated at 4°C overnight. The membranes were washed three times with 1X TBS containing 1% Tween-20 (10 min each time) before and after incubation with the secondary antibody (goat anti rabbit IgG-HRP; Cell Signaling Technology, Inc.; cat. no. 7074) diluted with 1X TBST at 1:2,000. The blots were visualized using ECL (cat. no. 32106; Thermo Fisher Scientific, Inc.) in a dark room. The
protein expression levels for each specimen were calculated using Quantity-One 4.6.6 (Bio-Rad Laboratories, Inc.).

Statistical analysis. All data are presented as the mean ± standard deviation. SPSS 22.0 software (IBM, Corp.) was used to analyze the data. The statistical significance between two groups of quantitative data were calculated by Student’s t-test. A comparison of constituent ratios was conducted using the \( \chi^2 \) test and \( \chi^2 \) test of paired quadrilaterals. Correlations in the data were identified and evaluated using correlation analysis of paired quadrilaterals. \( P<0.05 \) was considered to indicate a statistically significant difference.

Results

Promoter DEUP1 hypermethylation in HCC tissues. The bioinformatic analysis indicated that increased expression of DEUP1 was associated with a higher rate of patient overall survival (Fig. 1) and the degree of promoter methylation in HCC tissues was significantly increased compared with the adjacent non-cancerous tissues (\( P<0.01 \); Fig. 2). This suggests that DEUP1 may be a tumor suppressor gene and promoter methylation may play an important role in the development of HCC occurrence. The results of BSP demonstrated that DEUP1 promoter hypermethylation was detected in 46 of 60 (76.7%) tumors tissues, while only 5 of 60 in adjacent non-tumor tissues. DEUP1 promoter methylation levels in HCC were tissues significantly increased compared with the adjacent non-tumor tissues (\( P<0.01 \); Fig. 3).

DEUP1 mRNA expression in HCC tumor and adjacent non-tumor tissues. RT-PCR results demonstrated that 45 of the 60 HCC tissues had reduced or absent DEUP1 mRNA expression compared with adjacent non-cancerous tissues. All adjacent non-tumor tissues showed DEUP1 expression. Representative results are shown in Fig. 4; the expression of DEUP1 mRNA in the adjacent non-cancerous tissues was significantly increased compared with the HCC tissues (\( P<0.01 \)).

DEUP1 protein expression in HCC tumor and adjacent non-tumor tissues. The expression of DEUP1 protein was

Table I. Correlation of deuterosome assembly protein 1 mRNA expression with clinicopathological features in hepatocellular carcinoma.

| Clinical data                  | Number | Positive | Negative | Positive rate (%) | P-value |
|-------------------------------|--------|----------|----------|-------------------|---------|
| Sex                           |        |          |          |                   |         |
| Man                           | 45     | 10       | 35       | 22.3              | 0.606   |
| Woman                         | 15     | 5        | 10       | 33.3              |         |
| Age                           |        |          |          |                   |         |
| ≤50                           | 40     | 8        | 32       | 20.0              | 0.206   |
| >50                           | 20     | 7        | 13       | 35.0              |         |
| Tumor size                    |        |          |          |                   |         |
| ≤5 cm                         | 27     | 6        | 21       | 22.2              | 0.653   |
| >5 cm                         | 33     | 9        | 24       | 27.3              |         |
| HBsAg                         |        |          |          |                   |         |
| +                              | 44     | 9        | 35       | 20.5              | 0.312   |
| -                              | 16     | 6        | 10       | 37.5              |         |
| TNM stage                     |        |          |          |                   |         |
| I+II                          | 32     | 12       | 20       | 37.5              | 0.017   |
| III+IV                        | 28     | 3        | 25       | 10.7              |         |
| Portal tumor thrombosis       |        |          |          |                   |         |
| No                            | 52     | 11       | 41       | 21.2              | 0.188   |
| Yes                           | 8      | 4        | 4        | 50.0              |         |
| AFP                           |        |          |          |                   |         |
| ≤400 µg/l                     | 41     | 12       | 29       | 29.3              | 0.423   |
| >400 µg/l                     | 19     | 3        | 16       | 15.8              |         |
| Tumor differentiation         |        |          |          |                   |         |
| Poor                          | 35     | 5        | 30       | 14.3              | 0.023   |
| moderate-well                 | 25     | 10       | 15       | 40.0              |         |

TNM, tumor node metastasis; AFP, alpha fetoprotein.
YU et al: EXPRESSION AND METHYLATION OF THE DEUP1 PROMOTER IN HEPATOCELLULAR CARCINOMA

further analyzed in the 60 HCC tumor and adjacent non-tumor tissues. IHC results revealed that the positive expression of the DEUP1 protein was mainly located in the cytoplasm, represented by yellow or pale-brown granules (Fig. 5). A total of 48 out of the 60 HCC tumor tissues showed low or no DEUP1 protein expression. Both IHC and western blotting indicated that the expression of DEUP1 in adjacent non-tumor tissues was significantly increased compared with in HCC tissues (P<0.01; Fig. 6).

Association between DEUP1 promoter methylation and expression, and clinicopathologic parameters in HCC. Downregulated expression of DEUP1 mRNA and protein were significantly associated with TNM stage and tumor differentiation (P<0.05; Tables I and II). The DEUP1 promoter hypermethylation were associated with TNM stage and tumor differentiation. (Table III). DEUP1 mRNA, protein and the promoter methylation status had no association with other clinicopathological parameters.

Correlation between DEUP1 promoter methylation and protein expression. Out of the 60 patients with HCC, 46 had positive DEUP1 promoter methylation and six had positive protein expression. Among the 14 patients with a negative methylation status, six showed protein expression (Table IV). The protein expression of DEUP1 was negatively correlated with promoter methylation. Correlations were statistically significant (P<0.05).

Discussion

DNA methylation is an epigenetic phenomenon. It is considered the second strike for inactivation of tumor suppressor genes after mutation and allele loss (13). DEUP1, also known as coiled-up coil coiled-coil domain-containing 67 (CCDC67), is located on human chromosome 11q2.1, encoding 604 amino acids (11). It is a member of CCDC protein family. CCDC protein is composed of 180-220 amino acids and the quaternary structure in the coiled coil may be associated with angiogenin and other protein features and exhibit diverse functions related to their highly versatile folding motif (10,11), but little is known about DEUP1 function (14-16). The results of a bioinformatic predictive analysis indicated that inactivation of DEUP1 in HCC

Table II. Correlation of deutosome assembly protein 1 protein expression with clinicopathological features in hepatocellular carcinoma.

| Clinical data         | Number | Positive | Negative | Positive rate (%) | P-value |
|-----------------------|--------|----------|----------|-------------------|---------|
| Sex                   |        |          |          |                   |         |
| Man                   | 45     | 8        | 37       | 17.8              | 0.709   |
| Woman                 | 15     | 4        | 11       | 26.7              |         |
| Age                   |        |          |          |                   |         |
| ≤50                   | 40     | 7        | 33       | 17.5              | 0.732   |
| >50                   | 20     | 5        | 15       | 25.0              |         |
| Tumor size            |        |          |          |                   |         |
| ≤5 cm                 | 27     | 4        | 23       | 14.8              | 0.364   |
| >5 cm                 | 33     | 8        | 25       | 24.2              |         |
| HBsAg                 |        |          |          |                   |         |
| +                     | 44     | 7        | 37       | 15.9              | 0.343   |
| -                     | 16     | 5        | 11       | 31.3              |         |
| TNM stage             |        |          |          |                   |         |
| I+II                  | 32     | 10       | 22       | 31.3              | 0.020   |
| III+IV                | 28     | 2        | 26       | 7.1               |         |
| Portal tumor thrombosis|      |          |          |                   |         |
| No                    | 52     | 9        | 43       | 17.3              | 0.393   |
| Yes                   | 8      | 3        | 5        | 37.5              |         |
| AFP                   |        |          |          |                   |         |
| ≤400 µg/l             | 41     | 10       | 31       | 24.4              | 0.367   |
| >400 µg/l             | 19     | 2        | 17       | 10.5              |         |
| Tumor differentiation |        |          |          |                   |         |
| Poor                  | 35     | 3        | 32       | 8.6               | 0.009   |
| moderate-well         | 25     | 9        | 16       | 36.0              |         |

TNM, tumor node metastasis; AFP, alpha fetoprotein.
could be caused by methylation of a DNA CpG island. The expression of DEUP1 is associated with a high rate of patient survival. Furthermore, the expression of DEUP1 has been reported to be absent or significantly reduced in a number of tumors (10,11). Epigenetic changes, especially the methylation of DNA CpG islands, are one of the most important mechanisms behind low or non-expression of mRNA (17,18). Whether DEUP1 functions as a tumor suppressor gene in HCC as well as an inactivation mechanism in HCC has not been reported.

DEUP1 mRNA expression was increased in HCC tissues compared with in adjacent non-tumor tissues in the present study. Statistical analysis of DEUP1 mRNA expression and clinicopathological parameters indicated that DEUP1 mRNA expression in TNM stage I+II and III+IV was 37.5% (12/32) and 10.7% (3/28), respectively. In the poor and moderate-well differentiation groups, the expression of DEUP1 mRNA was 14.3% (5/35) and 40.0% (10/25), respectively, suggesting that mRNA expression is associated with the degree of malignancy of HCC.

The methylation of the DEUP1 promoter in HCC and adjacent non-tumor tissues was detected by BSP. The results indicated that methylation levels in HCC were increased compared with in the corresponding para-carcinoma tissues, indicating that methylation might be involved in the occurrence and development of HCC. Methylation levels in TNM stage I+II and III+IV were 65.6% (21/32) and 89.3% (25/28), respectively, and 88.6% (31/35) and 60.0% (15/25) in the low and moderate-well groups, respectively. These data indicated that the methylation status of DEUP1 has the potential to

---

**Table III. Correlation between Methylation of DEUP1 and clinicopathological features in HCC.**

| Clinical data      | Number | Methylated | Unmethylated | Positive rate (%) | P-value |
|--------------------|--------|------------|--------------|-------------------|---------|
| Sex                |        |            |              |                   |         |
| Man                | 45     | 37         | 8            | 82.2              | 0.159   |
| Woman              | 15     | 9          | 6            | 60.0              |         |
| Age                |        |            |              |                   |         |
| ≤50                | 40     | 33         | 7            | 82.5              | 0.235   |
| >50                | 20     | 13         | 7            | 65.0              |         |
| Tumor size         |        |            |              |                   |         |
| ≤5 cm              | 27     | 22         | 5            | 81.5              | 0.425   |
| >5 cm              | 33     | 24         | 9            | 72.7              |         |
| HBsAg              |        |            |              |                   |         |
| +                  | 44     | 36         | 8            | 81.8              | 0.223   |
| -                  | 16     | 10         | 6            | 62.5              |         |
| TNM stage          |        |            |              |                   |         |
| I+II               | 32     | 21         | 11           | 65.6              | 0.031   |
| III+IV             | 28     | 25         | 3            | 89.3              |         |
| Portal tumor thrombosis |  |        |              |                   |         |
| No                 | 52     | 41         | 11           | 78.8              | 0.570   |
| Yes                | 8      | 5          | 3            | 62.5              |         |
| AFP                |        |            |              |                   |         |
| ≤400 µg/l          | 41     | 32         | 9            | 78.0              | 0.965   |
| >400 µg/l          | 19     | 14         | 5            | 73.7              |         |
| Tumor differentiation |      |            |              |                   |         |
| Poor               | 35     | 31         | 4            | 88.6              | 0.010   |
| Moderate-well      | 25     | 15         | 10           | 60.0              |         |

HCC, hepatocellular carcinoma; TNM, tumor node metastasis; DEUP1, deuterosome assembly protein 1; AFP, alpha fetoprotein.

---

**Table IV. Correlation of deuterosome assembly protein 1 promoter methylation with protein expression in hepatocellular carcinoma.**

| Protein        | Methylation | P-value |
|----------------|-------------|---------|
|                | Positive    | Negative | Total |
| Positive       | 6           | 6        | 12    |
| Negative       | 40          | 8        | 48    |
| Total          | 46          | 14       | 60    |

P=0.039.
guide prognostic evaluation for HCC. Yin et al (10) reported that, as a tumor suppressor gene, the methylation of the gene promoter led to its inactivation, playing an important role in the occurrence and development of papillary thyroid carcinoma. Park et al (11) found that methylation of the DEUP1 promoter led to a decrease in DEUP1 expression and had an important role in gastric cancer. To further confirm the influence of DEUP1 expression on the development of HCC, the expression of the DEUP1 protein in HCC was detected by IHC and western blotting. The DEUP1 protein is located in the cytoplasm and its expression in HCC tissues was decreased compared with in adjacent non-tumor tissues. Furthermore, DEUP1 protein expression was associated with TNM stage and tumor differentiation.

It was also found that in the 46 HCC patients with promoter methylation, 40 did not have DEUP1 protein expression. The analysis indicated that methylation of the DEUP1 promoter had a negative correlation with protein expression, suggesting that gene promoter methylation may be an important mechanism underlying non-expression of the protein.

Methylation of one or more tumor suppressor gene CpG islands occurs in a number of malignant tumors (19-23). The inactivation of these genes has multiple effects on cellular processes such as apoptosis and cell cycle regulation, leading to tumorigenesis. CpG island methylation is a reversible epigenetic gene modification process (24). In healthy individuals, genes are in a low-methylation status and methylation inhibition does not influence gene expression in normal cells. Methylation of tumor suppressor gene CpG islands can render normal cells cancerous and demethylation can revert the phenotype of tumor cells back to normal, therefore providing new avenues for the therapy of tumors (25).

In conclusion, DEUP1 is a new tumor suppressor gene in HCC, with important regulatory effects on its occurrence, development and prognosis. This study lays a foundation for future studies on DEUP1 functions and the mechanisms of gene silencing in HCC, and may provide insights into demethylation drugs and new therapeutic targets. However, if the aim is to better to prove that DEUP1 is a suppressor gene in HCC and its promoter methylation results in low expression, cell experiments and animal experiments can be performed. The lack of further validation makes this study imperfect and the authors will follow up on cell and animal experiments to improve this study.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81701946) and the Science and Technology Department of Henan Province (grants no. 162300410121).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

QWY, SLC and HWT performed the experiment, SIZ, WZG and JL designed the study, QWY and SLC prepared and wrote the study. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Informed consent was obtained from each patient and the study protocol was approved by the Medical Ethics Committee of the First Affiliated Hospital of Zhengzhou University.

Patient consent for publication

Informed consent was obtained from each patient.

Competing interests

The authors declare that they have no competing interests.

References

1. Na TY, Ka NL, Rhee H, Kyeong D, Kim MH, Seong JK, Park YN and Lee MO: Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma. Oncogene 35: 5435-5445, 2016.
2. Branda M and Wands JR: Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 43: 891-902, 2006.
3. Wahid B, Ali A, Rafique S and Idrees M: New insights into the epigenetics of hepatocellular carcinoma. Biomed Res Int 2017: 1605875, 2017.
4. Zhang X, Cheng Q, Yin H and Yang G: Regulation of autophagy and EMT by the interplay between p53 and RAS during cancer progression (Review). Int J Oncol 51: 18-24, 2017.
5. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, et al: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603-4609, 2007.
6. Amato RJ: Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer 5: 422-426, 2007.
7. Wang Y, Zhang J, Xiao X, Liu H, Wang F, Li S, Wen Y, Wei Y, Su J and Zhang Y: The identification of age-associated cancer markers by an integrative analysis of dynamic DNA methylation changes. Sci Rep 6: 22722, 2016.
8. Pfeifer GP: Pertaining driver DNA methylation changes in human cancer. Int J Mol Sci 19: E1166, 2018.
9. Chen Y, Luo D, Tian W, Li Z and Zhang X: Demethylation of miR-495 inhibits cell proliferation, migration and promotes apoptosis by targeting STAT-3 in breast cancer. Oncol Rep 37: 3581-3589, 2017.
10. Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z, Zhou Y and Xing M: Characterization of the novel tumor-suppresser gene CCDC67 in papillary thyroid carcinoma. Oncotarget 7: 5830-5841, 2016.
11. Park SJ, Jang HR, Kim M, Kim JH, Kwon OH, Park JL, Noh SM, Song KS, Kim SY, Kim YH and Kim YS: Epigenetic alteration of CCDC67 and its tumor suppressor function in gastric cancer. Carcinogenesis 33: 1494-1501, 2012.
12. Kamarajah SK, Frankel TL, Sonnenday C, Cho CS and Nathan H: Critical evaluation of the american joint commission on cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis. J Surg Oncol 117: 644-650, 2018.
13. Böck J, Appenzeller S, Haertle L, Schneider T, Gehrig A, Schröder J, Rost S, Wolf B, Bartram CR, Sutter C and Haaf T: Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients. Int J Cancer 143: 1416-1425, 2018.
14. Murphy GA, Spedale EJ, Powell ST, Pilus L, Schultz SC and Chen L: The Sir4 C-terminal coiled coil is required for telomeric and mating type silencing in Saccharomyces cerevisiae. J Mol Biol 334: 769-780, 2003.

15. Tamaki H, Sanda M, Katsumata O, Haray Y, Fukaya M and Sakagami H: Pili is a coiled-coil domain-containing protein that localizes at the trans-Golgi complex and regulates its structure. FEBS Lett 586: 3064-3070, 2012.

16. Burkhard P, Stetefeld J and Strelkov SV: Coiled coils: A highly versatile protein folding motif. Trends Cell Biol 11: 82-88, 2001.

17. Zeng JD, Zhang N, Zhao GJ, Xu LX, Yang Y, Xu XY, Chen MK, Wang HY, Zheng SX and Li XX: MT1G is silenced by DNA methylation and contributes to the pathogenesis of hepatocellular carcinoma. J Cancer 9: 2807-2816, 2018.

18. Kishino T, Niwa T, Yamashita S, Takahashi T, Nakazato H, Nakajima T, Igaki H, Tachimori Y, Suzuki Y and Ushijima T: Integrated analysis of DNA methylation and mutations in esophageal squamous cell carcinoma. Mol Carcinog 55: 2077-2088, 2016.

19. Kwon K, Song K, Han C, Zhang J, Lu L, Chen W and Wu T: Epigenetic silencing of miRNA-34a in human cholangiocarcinoma via EZH2 and DNA methylation impact on regulation of Notch pathway. Am J Pathol 187: 2288-2299, 2017.

20. Alipour M, Zargar SJ, Safarian S, Fouladdeh S, Azizi E and Jafargholizadeh N: The study of DNA methylation of bax gene promoter in breast and colorectal carcinoma cell lines. Iran J Cancer Prev 6: 59-64, 2013.

21. Lu Y, Zabihula B, Yibulayin W and Liu X: Methylation and expression of RECK, P53 and RUNX genes in patients with esophageal cancer. Oncol Lett 14: 5293-5298, 2017.

22. Zheng J, Mei Y, Xiang P, Zhai G, Zhao N, Xu C, Liu M, Pan Z, Tang K and Jia D: DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition. Cancer Cell Int 18: 56, 2018.

23. Song L, Yu H and Li Y: Diagnosis of lung cancer by SHOX2 gene methylation assay. Mol Diagn Ther 19: 159-167, 2015.

24. Sajadian SO, Ehnert S, Vakilian H, Koutsouraki E, Damm G, Seebohr D, Thasler W, Dooley S, Baharvand H, Sipos B and Nussler AK: Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma. Clin Epigenetics 7: 98, 2015.

25. Zahnow CA, Topper M, Stone M, Murray-Stewart T, Li H, Baylin SB and Casero RA Jr: Inhibitors of DNA methylation, histone deacetylation, and histone demethylation: A perfect combination for cancer therapy. Adv Cancer Res 130: 55-111, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.